NEW YORK, NY / ACCESSWIRE / December 18, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Lionbridge Technologies Inc. (NASDAQ: LIOX), Ceres Inc. (NASDAQ: CERE), Tejon Ranch Co. (NYSE: TRC) and OncoGenex Pharmaceuticals Inc. (NASDAQ: OGXI). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
To access our full PDF Research Packages for free, please visit the links below.
============
Full PDF DOWNLOAD Links
(You may have to copy and paste the links into your browser)
LIOX Research Package: http://www.traders-choice.com/pdf?s=LIOX
CERE Research Package: http://www.traders-choice.com/pdf?s=CERE
TRC Research Package: http://www.traders-choice.com/pdf?s=TRC
OGXI Research Package: http://www.traders-choice.com/pdf?s=OGXI
============
Highlights from today's reports include:
On Thursday, December 17, 2015, the NASDAQ Composite ended at 5,002.55, down 1.35%, the Dow Jones Industrial Average declined 1.43% to finish the day at 17,495.84 and the S&P 500 closed at 2,041.89, down 1.5%.
- Lionbridge Technologies Inc.'s stock decreased by 2.52% to close Thursday's session at USD 4.65. The company's shares fluctuated in the range of USD 4.63 and USD 4.81. A total of 0.18 million shares exchanged hands, which was lesser than its 50-day daily average volume of 0.22 million shares and was below its 52-week average volume of 0.24 million shares. Over the last three days, Lionbridge Technologies Inc.'s shares have advanced 1.53% while in the past one week, the stock has moved down 2.72%. Over the last three months, the stock has lost 7.55% and in the past six months, the shares have shed 25.36%. The stock traded below its 50-day and 200-day moving averages of USD 5.31 and USD 5.59, respectively. Further, the company is trading at a price to earnings ratio of 29.06 and AT a price to book ratio of 3.25. Additionally, the stock is trading at a price to cash flow ratio of 10.09.
- Ceres Inc.'s stock slipped by 0.29% to end Thursday's session at USD 0.34. The stock traded below its 50-day and 200-day moving averages of USD 0.93 and USD 1.59, respectively. The company's shares oscillated between USD 0.34 and USD 0.38. The stock recorded a trading volume of 2.44 million shares, which was above its 50-day daily average volume of 0.29 million shares and above its 52-week average volume of 0.43 million shares. Over the last five days, Ceres Inc.'s shares have declined by 54.19% and in the past one month, the stock has lost 63.55%. In addition, over the last three months, the stock has lost 69.46% and year to date, the shares have shed 82.36%. Further, Ceres Inc. is trading at a price to book ratio of 0.7. The price to sales ratio was recorded at 0.8.
- Tejon Ranch Co.'s stock declined 2.64% to finish Thursday's session at USD 19.20, much below its 50-day and 200-day moving averages of USD 21.86 and USD 24.02, respectively. The share price oscillated between USD 19.20 and USD 19.75. The stock recorded a trading volume of 0.043 million shares, which was above its 50-day daily average volume of 0.037 million shares and above its 52-week average volume of 0.038 million shares. Over the last three days, Tejon Ranch Co.'s shares have declined by 1.54% and in the past one week, the stock has moved down 0.83%. Moreover, in the last six months, the stock has lost 22.86% and year to date, the shares have shed 34.83%. Further, the company is trading at a price to earnings ratio of 126.17 and at a price to book ratio of 1.38. Additionally, the stock is trading at a price to cash flow ratio of 58.27 and at a price to sales ratio of 6.87.
- OncoGenex Pharmaceuticals Inc.'s stock added 3.48% to close Thursday's session at USD 1.19. The company's shares oscillated between USD 1.14 and USD 1.27. The stock recorded a trading volume of 0.51 million shares, which was above its 50-day daily average volume of 0.47 million shares while below its 150-day daily average volume of 0.67 million shares. Over the last five days, OncoGenex Pharmaceuticals Inc's shares have advanced 3.48% while in the past one month, the stock has lost 51.43%. In addition, over the last three months, the stock has lost 57.80% and year to date, the shares have shed 48.03%. The stock is at a price to book ratio of 0.88. The historical PB ratio is near to 1.52. Additionally, the stock is trading at a price to sales ratio of 1.93. Further the stock is having a 52- week range of USD 1.11- USD 4.10.
About Trader's Choice:
Trader's Choice ("TC") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. TC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
TC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein. The information in this release has been sourced from a third party data base.
NO WARRANTY
TC, the Author and the Reviewer (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.traders-choice.com/.
RESTRICTIONS
TC is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
E-mail: press (at) traders-choice.com
SOURCE: Trader's Choice